BTG2 acts as an inducer of muscle stem cell senescence

Baozhou Peng,Yihan Chen,Yaning Wang,Yixi Fu,Xinrui Zeng,Hanmeng Zhou,Zibaidan Abulaiti,Shuaiyu Wang,Hongbo Zhang
DOI: https://doi.org/10.1016/j.bbrc.2023.05.098
2023-08-20
Abstract:Background: Muscle aging is associated with muscle stem cell (MuSC) senescence, a process of whose DNA damage accumulation is considered as one of the leading causes. BTG2 had been identified as a mediator of genotoxic and cellular stress signaling pathways, however, its role in senescence of stem cells, including MuSC, remains unknown. Method: We first compared MuSCs isolated from young and old mice to evaluate our in vitro model of natural senescence. CCK8 and EdU assays were utilized to assess the proliferation capacity of the MuSCs. Cellular senescence was further assessed at biochemical levels by SA-β-Gal and γHA2.X staining, and at molecular levels by quantifying the expression of senescence-associated genes. Next, by performing genetic analysis, we identified Btg2 as a potential regulator of MuSC senescence, which was experimentally validated by Btg2 overexpression and knockdown in primary MuSCs. Lastly, we extended our research to humans by analyzing the potential links between BTG2 and muscle function decline in aging. Results: BTG2 is highly expressed in MuSCs from elder mice showing senescent phenotypes. Overexpression and knockdown of Btg2 stimulates and prevents MuSCs senescence, respectively. In humans, high level of BTG2 is associated with low muscle mass in aging, and is a risk factor of aging-related diseases, such as diabetic retinopathy and HDL cholesterol. Conclusion: Our work demonstrates BTG2 as a regulator of MuSC senescence and may serve as an intervention target for muscle aging.
What problem does this paper attempt to address?